RAPT Therapeutics Files 8-K Report

Rapt Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyRapt Therapeutics, Inc.
Form Type8-K
Filed DateOct 20, 2025
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, corporate-disclosure

TL;DR

RAPT Therapeutics filed a routine 8-K with the SEC on Oct 20, 2025.

AI Summary

On October 20, 2025, RAPT Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, but the filing indicates a standard corporate reporting event.

Why It Matters

This filing indicates RAPT Therapeutics is making a standard disclosure to the SEC, which could contain updates on corporate events or financial information relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate disclosure of significant negative events.

Key Players & Entities

  • RAPT Therapeutics, Inc. (company) — Registrant
  • October 20, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 001-38997 (company_id) — SEC File Number
  • 47-3313701 (tax_id) — IRS Employer Identification No.
  • 561 Eccles Avenue, South San Francisco, California 94080 (address) — Principal Executive Offices
  • (650) 489-9000 (phone_number) — Registrant's Telephone Number

FAQ

What specific event triggered this 8-K filing on October 20, 2025?

The filing indicates it is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, but the specific triggering event is not detailed in the provided excerpt.

What is RAPT Therapeutics, Inc.'s primary business sector?

RAPT Therapeutics, Inc. is in the Pharmaceutical Preparations sector, SIC code 2834.

Where is RAPT Therapeutics, Inc. headquartered?

The company's principal executive offices are located at 561 Eccles Avenue, South San Francisco, California 94080.

When was RAPT Therapeutics, Inc. formerly known as FLX Bio, Inc.?

The company changed its name from FLX Bio, Inc. on May 4, 2016.

What is the SEC file number for RAPT Therapeutics, Inc.?

The SEC file number for RAPT Therapeutics, Inc. is 001-38997.

Filing Stats: 1,448 words · 6 min read · ~5 pages · Grade level 9.4 · Accepted 2025-10-20 08:02:29

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RAPT The Nasdaq

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. RAPT Therapeutics, Inc. (the "Company") is furnishing the investor presentation slides (the "Corporate Presentation") attached hereto as Exhibit 99.1, which the Company may use from time to time in conversations with investors and analysts. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

01 Other Events

Item 8.01 Other Events. On October 20, 2025, the Company and Shanghai Jeyou Pharmaceutical Co., Ltd. ("Jeyou," formerly called Shanghai Jemincare Pharmaceutical Co., Ltd.), a leading pharmaceutical company in China, announced positive topline data from Jeyou's phase 2 trial of RPT904 (JYB1904) (the "Phase 2 Trial") as monotherapy in chronic spontaneous urticaria ("CSU"). The Phase 2 Trial, which was conducted in China, was designed to evaluate the safety and efficacy of RPT904 at dosing intervals of 8 weeks ("Q8W") and 12 weeks ("Q12W") compared to omalizumab dosed every 4 weeks ("Q4W"). The Phase 2 Trial was not a formal non-inferiority study and no statistical hypothesis was tested. The data from the Phase 2 Trial indicate that RPT904 dosed Q8W or Q12W has comparable efficacy and safety to omalizumab dosed Q4W. The Company and Jeyou believe these results warrant advancing RPT904 to phase 3 development, and the Company plans to discuss next steps regarding development of RPT904 for CSU with the U.S. Food and Drug Administration and other regulatory authorities. The randomized, double-blind Phase 2 Trial enrolled 137 adult patients with CSU inadequately controlled by H1 antihistamines for a 16-week treatment period with patients randomized 1:1:1 across three arms. Patients randomized to the RPT904 Q8W arm received 300 mg subcutaneously ("SC") at Week 0 and Week 8, while patients randomized to the RPT904 Q12W arm received a single 300 mg SC dose at Week 0 (to represent a dosing interval of at least every 12 weeks). Patients randomized to the omalizumab Q4W arm received 300 mg SC at Weeks 0, 4, 8 and 12. The primary endpoint was change from baseline in the seven-day urticaria activity score ("UAS7") at Weeks 8, 12 and 16, and a key secondary endpoint was the proportion of patients with UAS7=0 at Weeks 8, 12 and 16. After the initial 16-week treatment period, patients were followed for an additional 16 weeks without additional treatment. The topline data reported h

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K (including the exhibit thereto) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "estimates," "expects," "look forward," "planned," "potential" "will" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the efficacy and safety profile of RPT904, the clinical development of RPT904, including timing of clinical trials and expectations of the Company and Jeyou to advance RPT904 to phase 3, plans for regulatory interactions, the therapeutic and commercial potential of RPT904, and other statements that are not historical fact. Many factors may cause differences between current expectations and actual results, including unexpected or unfavorable safety or efficacy data observed during clinical studies, preliminary data and trends that may not be predictive of future data or results or that may not demonstrate safety or efficacy or lead to regulatory approval, the Company's reliance on its partners and other third parties, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions (including the long-term impacts of ongoing overseas co

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAPT Therapeutics, Inc. Date: October 20, 2025 By: /s/ Rodney Young Rodney Young Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.